Lopinavir ritonavir: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''Lopinavir/ritonavir''' ([[International Nonproprietary Name|INNs]]) is a [[fixed dose combination (antiretroviral)|fixed dose combination]] drug for the treatment of [[HIV]] infection. It combines [[lopinavir]] (not available as a single drug) with a sub-therapeutic dose of [[ritonavir]] (trade name ''Norvir'') into a fixed-dose pill. | |||
The combination is marketed by [[Abbott Laboratories|Abbott]] as '''Kaletra''' (high-income countries) and '''Aluvia''' (low-income countries), as a component of combination therapy to treat HIV/[[AIDS]]. The Kaletra formulation has also been used successfully as monotherapy in some studies.<ref>{{cite web |url= http://www.aidsmap.com/iKaletrai-monotherapy-as-effective-as-triple-therapy-for-at-least-18-months/page/1424681/ |title=Kaletra monotherapy as effective as triple therapy for at least 18 months |first1=Christopher |last1=Gadd |first2=Keith |last2=Alcorn |publisher=[[aidsmap]] |work=aidsmap.com |date=18 August 2006 |accessdate=24 June 2011}}</ref> | |||
As of 2006, lopinavir/ritonavir forms part of the preferred combination for first-line therapy recommended by the United States Department of Health and Human Services (DHHS).<ref name="dhhs">DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from [http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 AIDSInfo])</ref> It is available as capsules, tablets and oral solution. | |||
==Category== | ==Category== | ||
Latest revision as of 03:22, 10 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Lopinavir/ritonavir (INNs) is a fixed dose combination drug for the treatment of HIV infection. It combines lopinavir (not available as a single drug) with a sub-therapeutic dose of ritonavir (trade name Norvir) into a fixed-dose pill.
The combination is marketed by Abbott as Kaletra (high-income countries) and Aluvia (low-income countries), as a component of combination therapy to treat HIV/AIDS. The Kaletra formulation has also been used successfully as monotherapy in some studies.[1]
As of 2006, lopinavir/ritonavir forms part of the preferred combination for first-line therapy recommended by the United States Department of Health and Human Services (DHHS).[2] It is available as capsules, tablets and oral solution.
Category
Antiretroviral
US Brand Names
KALETRA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Lopinavir is an antiviral drug. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.[3]
References
- ↑ Gadd, Christopher; Alcorn, Keith (18 August 2006). "Kaletra monotherapy as effective as triple therapy for at least 18 months". aidsmap.com. aidsmap. Retrieved 24 June 2011.
- ↑ DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from AIDSInfo)
- ↑ "KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.]". Text " accessdate" ignored (help)